Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 18/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 15/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 15/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4671845 | 0.84 | ADRB2 (0.57) | ADRB3ADRB2ADRB1 | |
| SCHEMBL4672343 | 0.83 | ADRB2 (0.58) | ADRB3ADRB2ADRB1 | |
| SCHEMBL4675124 | 0.83 | ADRB2 (0.46) | ADRB3ADRB2ADRB1 | |
| SCHEMBL6284162 | 0.79 | ADRB2 (0.50) | ADRB3ADRB2ADRB1 | |
| SCHEMBL6281088 | 0.79 | ADRB2 (0.48) | ADRB3ADRB2ADRB1 | |
| SCHEMBL6281091 | 0.79 | ADRB2 (0.48) | ADRB3ADRB2ADRB1 | |
| SCHEMBL4672101 | 0.79 | ADRB3 (0.41) | ADRB3ADRB2ADRB1 | |
| SCHEMBL4670486 | 0.79 | ADRB3 (0.41) | ADRB3ADRB2ADRB1 | |
| SCHEMBL4672102 | 0.79 | ADRB3 (0.41) | ADRB3ADRB2ADRB1 | |
| SCHEMBL4670116 | 0.79 | ADRB3 (0.41) | ADRB3ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1054881-B1 | NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | BAYER CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20040072843-A1 | Novel sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists | LADOUCEUR GAETAN H (US) | 2004-04-15 | — | — | US | disclosed |
| US-20030073839-A1 | Compounds useful for preparation of Beta-3 adrenoreceptor agonist | BAYER PHARMACEUTICALS CORPORATION | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072843-A1 | Novel sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB2 2/4885ADRB1 3/4885 |
| US-20030073839-A1 | Compounds useful for preparation of Beta-3 adrenoreceptor agonist | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB2 2/4885ADRB1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.